长链非编码RNA ILF3-AS1在临床常见恶性肿瘤中的研究进展

Research Progress of Long Non-coding RNA ILF3-AS1 in Common Malignant Tumors

恶性肿瘤起病隐匿,缺乏特异性症状和有效的诊断和治疗手段,确诊时多为晚期且预后不良。高通量测序技术的发展使得针对突变基因的个体化精准治疗成为新的方向。长链非编码RNA(lncRNA)在肿瘤的发生发展过程中发挥重要作用。白细胞介素增强子结合因子3-反义RNA 1(ILF3-AS1)作为一种新近发现的lncRNA在诸多临床常见恶性肿瘤中表达异常。lncRNA ILF3-AS1通过多种调控机制及信号通路促进恶性肿瘤细胞的增殖、迁移、侵袭和上皮-间充质转化过程,其表达水平与患者临床预后密切相关。因此,未来对lncRNA ILF3-AS1进行深入研究有助于相关恶性肿瘤的早期诊断、靶向治疗和预后评估。

Malignant tumors are featured with insidious onset,lack of specific symptoms and effective diagnostic and therapeutic tools,and are often diagnosed in the late stage with poor prognosis.The advancements of high-throughput sequencing techniques have made individualized precision therapy targeting mutated genes a new direction.Long non-coding RNA(lncRNA)plays important roles in the oncogenesis and development of various tumors.Interleukin enhancer binding factor 3-antisense RNA 1(ILF3-AS1),a kind of newly discovered lncRNA,is dysregulated in various common malignant tumors in clinical practice.LncRNA ILF3-AS1 promotes proliferation,migration,invasion,and epithelial-mesenchymal transition processes of malignant tumor cells through a variety of regulatory mechanisms and signaling pathways.Its expression level is closely related to the clinical prognosis of the patients.Therefore,in-depth research on lncRNA ILF3-AS1 in the future will be helpful for the early diagnosis,targeted therapy and prognostic assessment of relevant malignant tumors.